The short answer
The USPSTF grades PSA screening C for men 55 to 69, meaning an individual decision, and D at 70 and older. The benefits and harms are both real and both measurable.
The USPSTF gives PSA screening a Grade C for men aged 55 to 69, meaning it should be offered selectively after a discussion, and a Grade D for men 70 and older.
Per 1,000 men screened over about 13 years, screening prevents roughly 1.3 prostate cancer deaths and about 3 cases of metastatic prostate cancer.
More than 15 percent of men screened over 10 years get at least one false-positive result, and about 1 percent of prostate biopsies cause a complication requiring hospitalization.
An estimated 20 to 50 percent of prostate cancers found by screening may be overdiagnosed, meaning they would never have caused symptoms.
Choose how you want to understand this
The full explanation.
What the test is
PSA is a protein made by the prostate and measured with a blood draw. Prostate cancer tends to raise it. So does benign prostatic hyperplasia, prostatitis, a urinary infection, recent ejaculation, a long bicycle ride, and getting older. PSA is a signal that something is going on in the prostate, not a cancer test.
That ambiguity is the source of nearly every difficulty that follows.
What the USPSTF actually says
Two recommendations, not one.
Ages 55 to 69: Grade C. The Task Force recommends that the decision be an individual one, made after a clinician discusses the benefits and harms. A C means the net benefit is small, so preferences legitimately decide.
Ages 70 and older: Grade D. The Task Force recommends against routine PSA screening, having concluded the harms outweigh the benefits at that age.
The age split exists because the benefit takes about a decade to appear while the harms are immediate.
The benefits, per 1,000 men
Over approximately 13 years of follow-up, for every 1,000 men screened:
- About 1.3 deaths from prostate cancer are prevented.
- About 3 cases of metastatic prostate cancer are prevented.
Metastatic disease is worth naming alongside mortality, because avoiding it means avoiding bone pain, hormone therapy, and a substantially different course of illness even when death is not the endpoint.
These are small numbers. They are also real, and prostate cancer remains a leading cause of cancer death in men.
The harms, in the same units
False positives. More than 15 percent of men screened over 10 years have at least one elevated PSA that does not turn out to be cancer. Each leads to repeat testing, often MRI, and sometimes biopsy.
Biopsy complications. Roughly 1 percent of prostate biopsies produce a complication requiring hospitalization, most often infection or bleeding. Lesser effects such as pain and blood in the urine or semen are common.
Overdiagnosis. An estimated 20 to 50 percent of prostate cancers detected by screening may be overdiagnosed. This is the harm that is invisible to the person it happens to; the cancer is real, and there is no test that identifies which ones would never have progressed.
Treatment side effects. These are the numbers most worth sitting with:
- After radical prostatectomy, about 1 in 5 men develop long-term urinary incontinence.
- After radical prostatectomy, about 2 in 3 men develop long-term erectile dysfunction.
- After radiation, up to 1 in 6 men have long-term bothersome bowel symptoms.
These effects last years and often permanently, and they land on men who in many cases were never going to be harmed by the cancer.
What has changed, and why the grade moved
In 2012 the USPSTF gave PSA screening a D for all ages. In 2018 it revised that to a C for men 55 to 69 while keeping the D at 70 and older.
Two things moved. Longer follow-up from European trial data firmed up the small mortality benefit. And practice changed: active surveillance became the standard approach for low-risk cancer, and MRI before biopsy reduced the number of men biopsied unnecessarily. Both shrank the harm side of the ledger without changing the benefit side.
This matters for your decision because it means the older framing, that a PSA test leads inevitably to surgery, is no longer accurate. If you would choose active surveillance for a low-risk cancer, the arithmetic of screening looks meaningfully better than the raw treatment side-effect numbers suggest.
Who has more at stake
The risk is not uniform. Black men have higher prostate cancer incidence and higher mortality. A father or brother with prostate cancer raises risk, more so if they were diagnosed young.
The American Cancer Society frames this as timing of the conversation: at 50 for men at average risk with at least 10 years of life expectancy, at 45 for men at higher risk including Black men and those with a first-degree relative diagnosed before 65, and at 40 for men with several affected first-degree relatives diagnosed young.
Higher risk means more benefit per person screened. The harms stay the same, which is why it shifts the balance rather than settling it.
Making the decision
There is no answer that is right for everyone in the 55 to 69 band, which is the point of a Grade C. What helps is deciding in advance, before the blood draw, what you would do with each possible result. If your PSA came back elevated, would you want an MRI. If a low-risk cancer were found, would you accept active surveillance or would you want it treated.
Answering those questions first turns PSA from a test that makes decisions for you into one that informs decisions you have already thought through.
Sources
Words to know
Tap any term to see what it means.
Common questions
Should I get a PSA test or not?
For men aged 55 to 69, there is no single right answer, and that is precisely what a Grade C means. The numbers are small on both sides: about 1.3 prostate cancer deaths prevented per 1,000 men over 13 years, against a meaningful chance of a false positive, a biopsy, an overdiagnosed cancer, and treatment side effects. Men who weight avoiding a cancer death very heavily reasonably choose to screen. Men who weight avoiding incontinence, erectile dysfunction, and unnecessary treatment heavily reasonably choose not to. Both are informed choices.
Why does the USPSTF recommend against PSA testing at 70 and older?
Because the benefit takes many years to appear while the harms arrive immediately. Prostate cancer mortality reductions in the trials emerged after roughly a decade of follow-up. A man in his seventies is more likely to die of something else in that window, more likely to have complications from biopsy or treatment, and more likely to be diagnosed with a slow-growing cancer that would never have surfaced. That combination is what produces a Grade D.
My PSA is elevated. Does that mean I have cancer?
Usually not. PSA rises with benign prostatic hyperplasia, prostatitis, urinary infection, recent ejaculation, vigorous cycling, and simply with age. More than 15 percent of men screened over a decade have at least one false positive. The typical next steps are repeating the test, sometimes an MRI, and a biopsy only if concern persists. MRI before biopsy has become common specifically to avoid biopsies that were not going to find anything meaningful.
If cancer is found, do I have to be treated immediately?
No, and this has changed substantially. Many low-risk prostate cancers are now managed with active surveillance, meaning regular PSA tests, examinations, imaging, and repeat biopsies, with treatment held in reserve unless the cancer shows signs of progressing. Active surveillance is what allows some men to gain the benefit of finding a dangerous cancer without immediately accepting the incontinence and erectile dysfunction risks of surgery or radiation. Ask about it explicitly if a low-risk cancer is found.
I am Black, or my father had prostate cancer. Does that change things?
It changes the balance in favor of at least having the conversation, and having it earlier. Black men have higher prostate cancer incidence and mortality, and a father or brother with prostate cancer raises risk as well. The American Cancer Society suggests the discussion begin at 45 for men at higher risk and at 40 for those with several affected first-degree relatives who were diagnosed young. Higher baseline risk means the same test yields more benefit per person screened, though the harms remain unchanged.
Questions to ask your doctor
Being prepared helps you get the most out of your appointments. Save or print these questions.
Tap a question to save it to your list (kept on this device).
Speak With Trained Specialists & Human Navigators
Cancer Explained provides educational guidance, but does not replace trained specialists, social workers, or your medical team.
Talk to a trained cancer information specialist
Free, confidential assistance from NCI Cancer Information Service via phone, chat, or email.
Contact your oncology team
Locate after-hours contact numbers, portal messages, or urgent triage phone lines.
Find a patient navigator
Get one-on-one help with appointments, logistics, translation, and care coordination.
Find a genetic counselor
Discuss inherited mutation risk, family history, and genetic testing options.
Find an oncology social worker
Access emotional counseling, family support groups, and mental health resources.
Find a financial navigator
Locate copay assistance foundations, grant programs, and lodging/travel support.
Find a clinical-trial specialist
Search matching studies and speak with NCI trial information specialists.
Get urgent help
Immediate emergency guidance for fever (>100.4°F during chemo), severe pain, or shortness of breath.
Help Us Improve This Guide
Did this explanation answer your question and help you determine your next step?
Know someone who needs this?
Plenty of people are looking for something like this and do not know where to start. If this would help a friend or someone you love, send it on — we have written an opening line so you do not have to stare at an empty message. You can change every word of it.
Your message is written and sent in your own email or messaging app — we never see who you send it to, and nothing is added to any list.
Plain-language explanation of the federal sources cited on this page. AI-assisted, source-checked, not clinician-reviewed.
Written by: Cancer Explained Editorial TeamSources last checked: 2026-07-30Last updated: 2026-07-30Next planned review: 2027-07-30
How this page was created
Cancer Explained does not originate medical claims. Every page restates guidance already published by the National Cancer Institute, the CDC, the USPSTF and the FDA, in plain language, with the source cited so you can check the original yourself. AI does the translating and organizing; automated checks test claims, citations, clarity and safety before anything publishes. We do not employ clinicians and do not intend to — our work is translation and navigation, not clinical judgment. Nothing here is personal medical advice, and no page can account for your particular situation.
Editorial status — Source verified. This page was created with AI assistance and checked against the sources listed on it. Source checking is not a medical review.
General education — varies by person. Answers genuinely differ between people. This page explains what commonly varies and points you to your care team for your situation.
Human medical review: not completed. Cancer Explained is not clinician-reviewed, and that is a deliberate design choice rather than a gap we are waiting to close. We restate published federal guidance and cite it; the authority belongs to the source, not to us. That is why every page names where its claims come from — so you can verify us instead of trusting us. Use it to understand your situation and to ask better questions of the people treating you.
How this page was created
Cancer Explained does not originate medical claims. Every page restates guidance already published by the National Cancer Institute, the CDC, the USPSTF and the FDA, in plain language, with the source cited so you can check the original yourself. AI does the translating and organizing; automated checks test claims, citations, clarity and safety before anything publishes. We do not employ clinicians and do not intend to — our work is translation and navigation, not clinical judgment. Nothing here is personal medical advice, and no page can account for your particular situation.
Editorial status: Source verified — This page was created with AI assistance and checked against the sources listed on it. Source checking is not a medical review.
Human medical review: not completed. Cancer Explained is not clinician-reviewed, and that is a deliberate design choice rather than a gap we are waiting to close. We restate published federal guidance and cite it; the authority belongs to the source, not to us. That is why every page names where its claims come from — so you can verify us instead of trusting us. Use it to understand your situation and to ask better questions of the people treating you.
Read more about our editorial process, our use of AI, and our corrections policy.
Spotted a problem? Report an error — a factual mistake, broken or outdated source, confusing wording, or anything that seems unsafe. Please do not include names, medical record numbers, dates of birth, addresses, or other identifying medical information in your report.
After using this page, do you understand what to do next?
Anonymous — we only record the answer, never who gave it.
Related articles
Still have questions?
Educational answers, plain language
Free to print and share